Newsroom

Industry News

11 Oct

Intellipharmaceutics Announces US$4 Million Registered Direct Offering

TORONTO, Oct. 11, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, today announced that it entered into securities purchase agreements with certain institutional investors providing...

Read more

10 Oct

OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck’s KEYTRUDA® (pembrolizumab)

Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy Global study in the U.S. and Australia ImmunoPulse® IL-12 granted Fast Track and Orphan Drug Designation in the U.S. SAN DIEGO, Oct. 10, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company...

Read more

9 Oct

CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

– Interim phase 2 study results demonstrate the potential for superior efficacy and better tolerability over existing second-line therapy – CymaBay will also present new clinical research on pruritus, a symptom frequently affecting the quality of life for patients with primary biliary cholangitis – Company will host Post-AASLD Key...

Read more

9 Oct

FDA Grants Orphan Drug Designation to Trovagene’s PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)

SAN DIEGO, Oct. 9, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML) on September 28, 2017. PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor...

Read more

5 Oct

Aemetis Commercializes Advanced Enzymatic Biodiesel Process

Industry Breakthrough Significantly Lowers Feedstock and Process Costs CUPERTINO, CA / ACCESSWIRE / October 5, 2017 / Aemetis, Inc. (AMTX) announced today that its Universal Biofuels subsidiary in India has achieved a major milestone in the commercial production of advanced enzymatic biodiesel by processing one million pounds of low-cost waste...

Read more

4 Oct

Siyata Mobile Acquires Distribution Rights to Enterprise Workforce Software

MONTREAL, Quebec, Oct. 04, 2017 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (the “Company” or “Siyata“) (SIM.V) (SYATF) is pleased to announce it has entered into an agreement with an Israel based technology company for the acquisition (the “Transaction”) of distribution rights of an enterprise workforce hardware and software that...

Read more

4 Oct

Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City

NEWTOWN, Pa., Oct. 04, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that it will host a Key Opinion Leader (KOL) breakfast meeting on...

Read more

Page 10 of 268« First...89101112...203040...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address